Table 1.

Simultaneous increases in T cell CD47 expression and Caspase-10 activation precede post injury T cell anergy.

	Patients who Experienced T cell Anergy			Patients who NEVER Experienced T cell Anergy
	Pre-Anergy	During Anergy	Post-Anergy
T cell Proliferation to immobilized αCD3 antibody (Percent of matched Control)	99.3	31.0**	93.7	115.5
IL-2 secretion to αCD3 stimulation in 3 days culture (Percent of matched Control)	38.57†	11.42†	77.67	71.79
Caspase-10 Activation (Fold Change compared to matched Control)	5.4*	1.4	1.8	1.6
CD47 Expression (Fold Change compared to matched Control)	1.26##	1.14#	0.98	1.06
PD-1 Expression (Fold Change compared to matched Control)	1.14	1.57#	2.7##	1.2

All numbers represent median values. Fold changes in freshly isolated T cells’ expressions of active caspase-10 or PD-1 were determined as- (Percentage of patients’ T cells expressing active caspase-10 or PD-1 divided by percentage of parallel-processed control T cells expressing the same). Similarly fold changes in CD47 were determined as- [CD47 MFI in patients’ T cell/CD47 MFI in parallel-processed control T cells].

^**p < 0.001 vs. all other groups by Mann Whitney U test; n = 17 patients who experienced T cell anergy and 96 immunocompetent patients (who never experienced T cell anergy).

^†p < 0.05 compared to post-anergic T cells and T cells from immuno-competent patient group by t test; n = 3 for pre-anergy group, n = 11 for patients’ anergic T cell group, 3 for post anergic T cell group and 15 for immunocompetent T cell group.

^*p < 0.01 vs. all other groups by Mann Whitney U test; n = 6 for pre-anergy group, n = 16 for anergic T cell group, 13 for post anergic T cell group and 48 for immunocompetent T cell group.

^##p <0.01 and

^#p < 0.05 compared to post-anergic T cells and T cells from immuno-competent patient group by Mann Whitney U test; n= 8 patients who experienced T cell anergy and 92 immunocompetent patients.